 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 848465
Online Users : 1075
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/12907
|
| Title: | PT320, sustained-release exendin-4, mitigates L-DOPA-Induced dyskinesia in a rat 6-Hydroxydopamine model of Parkinson’s disease |
| Authors: | Yu, SJ;Chen, S;Yang, YY;Glotfelty, EJ;Jung, J;Kim, HK;Choi, HI;Choi, DS;Hoffer, BJ;Greig, NH;Wang, Y |
| Contributors: | Center for Neuropsychiatric Research |
| Abstract: | Background: We previously demonstrated that subcutaneous administration of PT320, a sustained-release (SR) form of exendin-4, resulted in the long-term maintenance of steady-state exenatide (exendin-4) plasma and target levels in 6-hydroxydopamine (6-OHDA)-pretreated animals. Additionally, pre- or post-treatment with PT320 mitigated the early stage of 6-OHDA-induced dopaminergic neurodegeneration. The purpose of this study was to evaluate the effect of PT320 on L-3,4-dihydroxyphenylalanine (L-DOPA)-induced abnormal involuntary movements (AIMs) in the rat 6-OHDA model of Parkinson’s disease. Methods: Adult male Sprague–Dawley rats were unilaterally lesioned in the right medial forebrain bundle by 6-OHDA. L-DOPA and benserazide were given daily for 22 days, starting from 4 weeks after lesioning. PT320 was co-administered weekly for 3 weeks. AIM was evaluated on days 1, 16, and 22 after initiating L-DOPA/benserazide + PT320 treatment. Brain tissues were subsequently collected for HPLC measurements of dopamine (DA) and metabolite concentrations. Results: L-DOPA/benserazide increased AIMs of limbs and axial as well as the sum of all dyskinesia scores (ALO) over 3 weeks. PT320 significantly reduced the AIM scores of limbs, orolingual, and ALO. Although PT320 did not alter DA levels in the lesioned striatum, PT320 significantly attenuated 6-OHDA-enhanced DA turnover. Conclusion: PT320 attenuates L-DOPA/benserazide-induced dyskinesia in a 6-OHDA rat model of PD and warrants clinical evaluation to mitigate Parkinson’s disease in humans. |
| Date: | 2020-08-11 |
| Relation: | Frontiers in Neuroscience. 2020 Aug 11;14:Article number 785. |
| Link to: | http://dx.doi.org/10.3389/fnins.2020.00785 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1662-453X&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000565356700001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85089893878 |
| Appears in Collections: | [王昀] 期刊論文
[劉誠珍] 期刊論文
|
Files in This Item:
| File |
Size | Format | |
|---|
| SCP85089893878.pdf | 3501Kb | Adobe PDF | 287 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
